Cambridge Healthtech Institute’s 8th Annual

Bispecific and Multispecific Antibody Therapeutics

24-25 April 2024

 

Bispecific and multispecific antibody research stands at the forefront of progress in cancer immunology, inspiring innovators and researchers alike as it paves the way for groundbreaking advancements. Despite recent strides, numerous formidable challenges remain, such as complex design, immunogenicity, limited half-life, off-target effects, lack of applications to solid tumors, tumor escape, improving yield, and reducing manufacturing costs. Here, we comprehensively explore the design, engineering, characterization, production, manufacturing, and clinical applications to bispecific and multispecific antibodies. Join us for Cambridge Healthtech Institute’s 8th Annual Bispecific and Multispecific Antibody Therapeutics Conference, where experts and visionaries gather to discuss solutions to the most persistent issues in this field.

 

Coverage will include, but is not limited to:

 

Design and Engineering:

  • AI applications
  • Modifying antibody format
  • Antigen selection
  • Combination approaches
  • Emerging targets
  • Fc region engineering
  • Incorporation of fusion proteins
  • Linker design optimization
  • Masking approaches
  • Modulating avidity-mediated binding specificity and affinity
  • Novel strategies and formats

 

Bi/Multispecific Characterization:

  • Improved functional assays
  • Predicting aggregation propensity
  • Stoichiometry considerations

 

Improving Safety and Stability:

  • Improving and assessing stability
  • Improving target localization
  • Mitigating cytokine release syndrome
  • Mitigating immunogenicity
  • Mitigating neurotoxicity
  • Reducing off-target effects
  • Regulatory compliance

 

Production and Manufacturing:

  • Cost-reduction strategies
  • Improving yield
  • Minimizing heterogeneity
  • Purification strategies
  • Quality control
  • Strategies for continuous manufacturing

 

Overcoming Challenges:

  • Addressing resistance and tumor escape
  • Improving applications to solid tumors
  • Mitigating size and pharmacokinetic limitations
  • Overcoming limited half-life
  • Reviving exhausted T cells with dual co-stimulation

 

Clinical Applications:

  • Applications to infections, inflammatory, and autoimmune diseases
  • Applications to neurological disorders
  • BiTE therapy
  • Checkpoint inhibition
  • Patient selection and personalization

 

The deadline for priority consideration is 6 October 2023.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

Opportunities for Participation:

 


For more details on the conference, please contact:

Nikki Cerniuk

Conference Producer

Cambridge Healthtech Institute

Phone: (+1) 781.972.1350

Email: ncerniuk@healthtech.com

 

For partnering and sponsorship information, please contact:

Phillip Zakim-Yacouby

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781.247.1815

Email: philzy@cambridgeinnovationinnstitute.com


Register Now